Erleada (apalutamide): A Leading Treatment Option for Prostate Cancer with Strong Market Growth Potential Developed by Janssen Pharmaceuticals, Erleada (apalutamide) has emerged as a pivotal therapeutic in the management of prostate cancer. As a non-steroidal anti-androgen, Erleada targets androgen receptors, which play a crucial role in the growth and spread of prostate cancer cells. This article delves into the market landscape, forecast, and emerging drug insights for Erleada through 2030. For More : https://www.delveinsight.com/sample-request/erleada-drug-insight-and-market-forecast